- Home
- FORA vs ANL Comparison
FORA vs ANL Comparison
Compare FORA & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- ANL
- Stock Information
- Founded
- FORA 2014
- ANL 2004
- Country
- FORA United States
- ANL Cayman Islands
- Employees
- FORA N/A
- ANL N/A
- Industry
- FORA Computer Software: Prepackaged Software
- ANL
- Sector
- FORA Technology
- ANL
- Exchange
- FORA Nasdaq
- ANL Nasdaq
- Market Cap
- FORA 64.0M
- ANL 73.8M
- IPO Year
- FORA N/A
- ANL 2023
- Fundamental
- Price
- FORA $2.15
- ANL $1.47
- Analyst Decision
- FORA Strong Buy
- ANL Buy
- Analyst Count
- FORA 1
- ANL 2
- Target Price
- FORA $5.00
- ANL N/A
- AVG Volume (30 Days)
- FORA 7.7K
- ANL 14.8K
- Earning Date
- FORA 08-13-2025
- ANL 08-08-2025
- Dividend Yield
- FORA N/A
- ANL N/A
- EPS Growth
- FORA N/A
- ANL N/A
- EPS
- FORA N/A
- ANL N/A
- Revenue
- FORA $22,332,001.00
- ANL N/A
- Revenue This Year
- FORA $13.31
- ANL N/A
- Revenue Next Year
- FORA $43.65
- ANL N/A
- P/E Ratio
- FORA N/A
- ANL N/A
- Revenue Growth
- FORA 5.22
- ANL N/A
- 52 Week Low
- FORA $1.85
- ANL $1.10
- 52 Week High
- FORA $4.03
- ANL $4.10
- Technical
- Relative Strength Index (RSI)
- FORA 56.15
- ANL 37.32
- Support Level
- FORA $1.95
- ANL $1.56
- Resistance Level
- FORA $2.09
- ANL $1.74
- Average True Range (ATR)
- FORA 0.11
- ANL 0.15
- MACD
- FORA 0.01
- ANL -0.01
- Stochastic Oscillator
- FORA 66.67
- ANL 12.50
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.